All Studies Meta Analysis Recent:

Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine

Sahraei et al., Int. J. Antimicrobial Agents, April 2020, 55:4, doi:10.1016/j.ijantimicag.2020.105945

Mar 2020

Twitter
Facebook

Source PDF All Studies Meta AnalysisMeta

Discussion of mechanisms of action, CQ vs. HCQ, early studies, safety.

Important missing comments or errors? Let us know.

Sahraei et al., 17 Mar 2020, peer-reviewed, 4 authors.

All Studies Meta Analysis Submit Updates or Corrections

This Paper HCQ All

Aminoquinolines against coronavirus disease 2019 (COVID-19): chloroquine or hydroxychloroquine

Zahra Sahraei, Minoosh Shabani, Shervin Shokouhi, Ali Saffaei

International Journal of Antimicrobial Agents, doi:10.1016/j.ijantimicag.2020.105945

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre -including this research content -immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Declarations Funding: None. Competing Interests: None declared. Ethical Approval: Not required.

References

Colson, Rolain, Raoult, Chloroquine for the 2019 novel coronavirus SARS-CoV-2, Int J Antimicrob Agents, doi:10.1016/j.ijantimicag.2020.105923

Gao, Tian, Yang, Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies, Biosci Trends, doi:10.5582/bst.2020.01047

Jorge, Melles, Zhang, Lu, Rai et al., Hydroxychloroquine prescription trends and predictors for excess dosing per recent ophthalmology guidelines, Arthritis Res Ther, doi:10.1186/s13075-018-1634-8

Lim, Im, Cho, Bae, Klein et al., Pharmacokinetics of hydroxychloroquine and its clinical implications in chemoprophylaxis against malaria caused by Plasmodium vivax, Antimicrob Agents Chemother, doi:10.1128/AAC.00339-08

Plantone, Koudriavtseva, Current and future use of chloroquine and hydroxychloroquine in infectious, immune, neoplastic, and neurological diseases: a mini-review, Clin Drug Investig, doi:10.1007/s40261-018-0656-y

Rainsford, Parke, Clifford-Rashotte, Kean, Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases, Inflammopharmacology, doi:10.1007/s10787-015-0239-y

Savarino, Boelaert, Cassone, Majori, Cauda, Effects of chloroquine on viral infections: an old drug against today's diseases?, Lancet Infect Dis, doi:10.1016/s1473-3099(03)00806-5

Tan, Yam, Sun, Chu, An evaluation of chloroquine as a broad-acting antiviral against hand, foot and mouth disease, Antiviral Res, doi:10.1016/j.antiviral.2017.11.017

Xu, Mugopen, Data, Group, Open access epidemiological data from the COVID-19 outbreak, Lancet Infect Dis, doi:10.1016/S1473-3099(20)30119-5

Download Image

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit

@CovidAnalysis

FAQ

Public domain CC0 1.0